Sponsor pipeline

Inhibrx clinical trial pipeline

Get alerts when Inhibrx's trials change

4 active trials 2 recruiting 1 Phase 3 8 disease areas 6 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-08-28

What changed in the last 30 days

2026-07-30
Primary completion pushed: 2026-10-30 → 2033-07
Primary endpoint(s) modified
Enrollment reopened
Enrollment increased: 296 → 340 participants
Completion pushed: 2027-05-12 → 2033-07
Trial arms changed: 14 → 15
NCT04198766 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in… · Phase 1/2

Active trials by phase

Phase 1
1
Phase 1/2
1
Phase 2
1
Phase 2/3
1

Active trials

NCT IDTitleConditionStatusUpdated
Phase 2/3
NCT06295731 INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC Head and Neck Squamous Cell Carcinoma (HNSCC) Active, Not Recruiting 2026-05-08
Phase 2
NCT04950075 Study of INBRX-109 in Conventional Chondrosarcoma Conventional Chondrosarcoma Active, Not Recruiting 2026-07-14
Phase 1/2
NCT04198766 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in… Solid Tumor Recruiting 2026-07-29
Phase 1
NCT03715933 Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors… Ewing Sarcoma Recruiting 2026-05-22

Disease areas by active trials

Sarcoma (2) · Head & Neck Cancer (2) · Non-Small Cell Lung Cancer (NSCLC) (1) · Lung Cancer (1) · Gastric Cancer (1) · Kidney Cancer (1) · Bladder Cancer (1) · Melanoma (1)

Get alerts when Inhibrx's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free